Introduction
============

Acute myeloid leukemia (AML) is a kind of heterogeneous disease characterized by the clonal expansion of hematopoietic stem cells (HSCs) or hematopoietic progenitor cells (HPCs) in the bone marrow (BM), blood, and other tissues without differentiation.[@b1-cmar-10-2489]

As sequencing methods have technologically advanced in the past four decades, next-generation sequencing (NGS) is now available for a detailed understanding of the molecular pathogenesis of AML.

*DNMTs* are genes that encode DNMTs for the methylation of CpG islands. As methylations reduce the expression of downstream genes, spontaneous defects in *DNMTs* lead to the instability of genome structure and thus increase the possibility of cancer.[@b2-cmar-10-2489] Since Ley et al[@b3-cmar-10-2489] confirmed that *DNMT3A* mutations were highly recurrent in patients with de novo AML and associated with a poor outcome, many prognostic studies about *DNMT3A*-mutated AML have been carried out.[@b4-cmar-10-2489]--[@b10-cmar-10-2489] Occurring in \~20% of AML patients and having a high proportion of *R882* mutation,[@b11-cmar-10-2489],[@b12-cmar-10-2489] *DNMT3A* mutations are often accompanied by *FLT3-ITD*, *NPM1*, *IDH1*, and *IDH2* mutations.[@b13-cmar-10-2489] *NPM1* mutations were more common in patients with *DNMT3A* mutations than in *DNMT3A* wild-type patients.[@b14-cmar-10-2489] High-risk *NPM1/FLT3* mutation (*NPM1*^wild^*/FLT3-ITD^negative^*, *NPM1*^wild^*/FLT3-ITD^positive^*, or *NPM1*^mut^*^/^FLT3-ITD^positive^*) was thought to be related with poor prognosis.[@b5-cmar-10-2489] Hematopoietic stem cell transplantation (HSCT) has been shown to benefit the survival of all AML patients with *DNMT3A* mutations.[@b8-cmar-10-2489],[@b9-cmar-10-2489] Gale et al[@b15-cmar-10-2489] argued that the presence of *DNMT3A* mutations should be considered as a poor-risk prognostic factor, irrespective of the *NPM1* genotype as it may disturb the outcome. There have been few studies concerning *DNMT3A* mutations alone in AML patients together with studying the biological and clinical features with companion genes. Therefore, understanding the biological and clinical characteristics of these patients with *DNMT3A* mutations is important for estimating their event-free survival (EFS) and overall survival (OS) and likely advantageous in deciding the most suited clinical treatment.

Patients and methods
====================

Patients
--------

We selected and enrolled 51 patients with diagnosed *DNMT3A*-mutated AML from The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>). We collected data including age, gender, AML French-American-British classification subtypes, karyotype, cytogenetics' risk, white blood cell (WBC) count, BM blasts percentage, peripheral blood (PB) blasts percentage, relapse, mutated recurrent genes, and combined mutation genes, which were highly related to AML such as *FLT3*, *IDH1/2*, *TET2*, *NRAS*, *CEBPA*, *PTPN11*, *KRAS*, *U2AF1*, *SMC1A*, *SMC3*, and *RAD21*, with their clinical figures to include EFS and OS. Gene mutations were detected by NGS. Written informed consent was obtained from all patients. This study was approved by the Human Research Ethics Committee of Washington University.

Statistical analyses
--------------------

The end points were EFS and OS. EFS is the time from the date of diagnosis to removal from the study due to the absence of complete remission, relapse, or death. OS is the time from the date of diagnosis to death due to any cause.

We compared different biological and clinical characteristics by using different statistical methods. The Student's *t*-test was applied to two group comparisons, and Chi-square test was used to compare the rate between them. Survival analysis was performed by Kaplan--Meier method. A two-sided *P*-value of \<0.05 was considered statistically significant. All statistical analyses were performed by the SPSS Version 20.0 software.

Results
=======

Biological and clinical characteristics
---------------------------------------

In all of the 51 patients, *NPM1* was the most frequently combined mutation gene (n=28, 54.9%), followed by *FLT3* (n=21, 41.2%), *IDH1* (n=11, 21.6%), and *TET2* (n=6, 11.8%). The mutational spectrum of all genes with \>5% mutation frequency is shown in [Figure 1](#f1-cmar-10-2489){ref-type="fig"}. The biological and clinical characteristics are summarized in [Table 1](#t1-cmar-10-2489){ref-type="table"}.

Patients were divided into two groups depending on their NPM1 mutation states. There were 23 patients with *DNMT3A*^mut^*/NPM1*^wild^ and 28 patients with *DNMT3A*^mut^*/NPM1*^mut^. The median age of the cohort was 58 years (24 men and 27 women; age range: 21--81 years), and 47.1% of the patients were ≥60 years. WBC counts ranged from 1.2 to 298.4×10^9^/L with a median of 45.0×10^9^/L, and 19 cases were not \<50×10^9^/L. The median BM blast percentage and PB blast percentage were 76 and 36%, respectively, and ranged from 32 to 100% and 0 to 97%; there were 30 (58.8%) cases with BM blasts ≥70% and six (30.0%) cases with PB blasts ≥70%. In 28 of the 51 patients (58.8%) who had relapses, days from collection to first relapse ranged from 53 to 1230 days with a median of 324.7 days. There were two (8.7%) cases with *FLT3-ITD* mutation and two (8.7%) cases with *FLT-TKD* mutation. HSCT treatments were received by 23 (45.1%) cases.

Upon comparing the two groups with *DNMT3A* mutations, we found that patients with *DNMT3A*^mut^*/NPM1*^mut^ had higher BM blasts (*P*=0.015), higher *FLT3-ITD/TKD* (*P*=0.004), and lower *IDH2* mutation (*P*=0.014). Other biological or clinical characteristics showed no significant differences between the two groups.

Comparison of EFS and OS between different biological and clinical characteristics
----------------------------------------------------------------------------------

To determine what kind of biological or clinical characteristics were easily influenced by *NPM1* mutation, we chose the following parameters for EFS and OS analyses: age (\<60 vs ≥60 years), cytogenetic risk (intermediate vs poor), WBC count (\<50×10^9^ vs ≥50×10^9^/L), BM blasts percentage (\<70 vs ≥70%), PB blasts percentage (\<70 vs ≥70%), mutated recurrent genes (\<5 vs ≥5), genes with no \<10 (19.6%) cases harboring *FLT3-ITD/TKD* and *IDH1* changes (mutation vs wild type), and HSCT (yes vs no). The results are shown in [Table 2](#t2-cmar-10-2489){ref-type="table"}.

The *NPM1* mutation had no influence on any of the abovementioned parameters in *DNMT3A*-mutated AML patients. EFS and OS between *DNMT3A*^mut^*/NPM1*^wild^ and *DNMT3A*^mut^*/NPM1*^mut^ groups showed no difference (*P*=0.504 and 0.586, respectively, [Figure 2A and B](#f2-cmar-10-2489){ref-type="fig"}). Furthermore, there was also no difference in EFS and OS between groups of patients with only chemical therapy (*P*=0.938 for EFS and *P*=0.942 for OS, [Figure 2C and D](#f2-cmar-10-2489){ref-type="fig"}) or HSCT treatment (*P*=0.940 for EFS and *P*=0.790 for OS, [Figure 2E and F](#f2-cmar-10-2489){ref-type="fig"}).

HSCT was an effective way for the treatment of *DNMT3A*-mutated AML patients (*P*=0.005 for EFS and *P*=0.001 for OS) in all of the 51 patients ([Figure 3A and B](#f3-cmar-10-2489){ref-type="fig"}). We also compared the influence of different treatments in each group. The group of people with *DNMT3A*^mut^*/NPM1*^wild^ derived the best of HSCT treatment and had longer EFS and OS than patients who received only chemical therapy (*P*=0.043 for EFS and *P*=0.008 for OS, [Figure 3C and D](#f3-cmar-10-2489){ref-type="fig"}). Patients in the other group with *DNMT3A*^mut^*/NPM1*^mut^ did not show similar results (*P*=0.056 for EFS and *P*=0.053 for OS, [Figure 3E and F](#f3-cmar-10-2489){ref-type="fig"}).

For further detailed analysis, we considered another subgroup of patients with *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^wild^ from the existing cohort of 51 patients. We compared the EFS and OS between *DNMT3A*^mut^*/FLT3*^wild^*/NPM1*^wild^ patients (n=19) and *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^wild^ patients (n=4) and found that there were significant differences between these two groups (*P*2=0.004 for EFS in [Figure 4A](#f4-cmar-10-2489){ref-type="fig"} and *P*2=0.001 for OS in [Figure 4B](#f4-cmar-10-2489){ref-type="fig"}), but there was no difference between the outcomes for the *DNMT3A*^mut^*/FLT3*^wild^*/NPM1*^wild^ and *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^mut^ groups (n=17, *P*1\>0.1, [Figure 4A and B](#f4-cmar-10-2489){ref-type="fig"}).

Discussion
==========

Our study showed that *DNMT3A* mutations in AML had higher BM blasts, higher *FLT3-ITD/TKD* mutation rate, and higher *IDH2* mutation rate when combined with *NPM1* mutation, but little difference in prognoses compared with *NPM1* wild type. HSCT treatment benefited all patients who carried the *DNMT3A* mutation and was a better choice for the *DNMT3A*^mut^*/NPM1*^wild^ group.

In Gale et al's[@b15-cmar-10-2489] study, 80% of 272 patients with *DNMT3A* mutation concomitantly had the *NPM1* mutation. We analyzed the biological and clinical features of 51 patients with *DNMT3A* mutations and found *NPM1* to be the most common accompanying mutation (n=28, 54.9%). This may be due to a relatively high percentage of patients older than 60 years in our study (47.1 vs 3%). Many genes participate in AML development.[@b16-cmar-10-2489] Mutations in *NPM1*, *IDH2*, and biallelic *CEBPA* are favorable risk factors;[@b13-cmar-10-2489] while *FLT3-ITD* positive, *IDH1*, *TET2*,[@b13-cmar-10-2489] *KRAS*,[@b17-cmar-10-2489] *U2AF1*, and *PTPN11* are always associated with poor outcomes.[@b18-cmar-10-2489],[@b19-cmar-10-2489] Although showing different mutation rates in AML patients, genes such as *NRAS*,[@b20-cmar-10-2489] *SMC1A*, *SMC3*, and *RAD21* showed no influence in the prognosis.[@b21-cmar-10-2489]

Holmberg et al[@b22-cmar-10-2489] did a basic clinical experiment on the relationship between *DNMT3A* and *NPM1* and found that deficiency in *DNMT3A* enhanced the rearrangement of heterochromatin, which was triggered by the loss of *NPM1*. In our study, 35.7% of *DNMT3A*^mut^*/NPM1*^mut^ patients harbored the *FLT3-ITD* mutation and this rate was similar to that reported by Gale et al[@b15-cmar-10-2489] (37%). Thol et al[@b5-cmar-10-2489] also found that patients with *DNMT3A* mutations were more likely to have mutations in *NPM1* with a trend toward a higher *FLT3* mutation rate. In our study, the *IDH2* mutation was seen in 21.7% patients in the *DNMT3A*^mut^*/NPM1*^wild^ group, while those in the *DNMT3A*^mut^*/NPM1*^mut^ group did not harbor the *IDH2* mutation. Another study showed that the percentage of *IDH2* mutations were 11.5 and 33.3% for *DNMT3A*^mut^*/NPM1*^wild^ and *DNMT3A*^mut^*/NPM1*^mut^, respectively.[@b15-cmar-10-2489] We were not very consistent with their *IDH2* mutation rates, and this may be related to the small number of cases.

Comparison of EFS and OS between different biological and clinical characteristics groups showed no difference. Similar to Xu et al's[@b23-cmar-10-2489] conclusion, we also confirmed that HSCT is a better option for patients with *DNMT3A* mutations. We found that chemical therapy and HSCT treatment had the same effect in the *DNMT3A*^mut^*/NPM1*^mut^ group. We supposed that this may be due to high mutation rate of *FLT3* in the *NPM1*-mutated group. Previous studies suggested that *FLT3-ITD* always results in significantly worse clinical outcomes and weakens the curative effect of conventional chemotherapy,[@b24-cmar-10-2489] as well as shortening the EFS and OS in *DNMT3A*-mutated patients.[@b25-cmar-10-2489] Only the *R140* mutation in *IDH2* seems to have prognostic meaning and is associated with a better outcome.[@b13-cmar-10-2489] In our study, we found that *IDH2* mutation only occurred in *DNMT3A*^mut^*/NPM1*^wild^ patients and three of the five *IDH2* mutations happened at the *R140* locus. This could be another reason why the *DNMT3A*^mut^*/NPM1*^mut^ group showed similar results to the *DNMT3A*^mut^*/NPM1*^wild^ group.

There are some limitations to our study. First, the small sample size may have reduced the accuracy of our results. Second, our study has a retrospective design, the effectiveness of which is limited when compared to a prospective study.

Conclusion
==========

All patients with the *DNMT3A* mutation benefited from HSCT, but those who also have *NPM1* mutations should be treated carefully given their high *FLT3-ITD/TKD* rate, and hence, HSCT may not be better than chemotherapy for this group of patients.
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![Mutational spectrum of all genes with \>5% mutation frequency.\
**Note:** *NPM1* was the most frequently combined mutation gene (n=28, 54.9%), followed by *FLT3* (n=21, 41.2%), *IDH1* (n=11, 21.6%), *TET2* (n=6, 11.8%), *SMC3* (n=6, 11.8%), *IDH2* (n=5, 9.8%), *NRAS* (n=5, 9.8%), *KRAS* (n=4, 7.8%), *MT-CYB* (n=4, 7.8%), *CEBPA* (n=3, 5.9%), *PTPN11* (n=3, 5.9%), *U2AF1* (n=3, 5.9%), *SMC1A* (n=3, 5.9%), and *RAD21* (n=3, 5.9%).](cmar-10-2489Fig1){#f1-cmar-10-2489}

![Comparison of EFS and OS between different biological and clinical character groups.\
**Notes:** (**A** and **B**) EFS and OS of *DNMT3A*^mut^*/NPM1*^wild^ vs *DNMT3A*^mut^*/NPM1*^mut^ in all of the 51 patients. (**C** and **D**) EFS and OS of *DNMT3A*^mut^*/NPM1*^wild^ vs *DNMT3A*^mut^*/NPM1*^mut^ in 28 patients with chemotherapy. (**E** and **F**) EFS and OS of *DNMT3A*^mut^*/NPM1*^wild^ vs *DNMT3A*^mut^*/NPM1*^mut^ in 23 patients with HSCT.\
**Abbreviations:** EFS, event-free survival; HSCT, hematopoietic stem cell transplantation; OS, overall survival.](cmar-10-2489Fig2){#f2-cmar-10-2489}

![Comparison of chemotherapy and HSCT in different mutation groups.\
**Notes:** (**A** and **B**) EFS and OS of all the 51 patients. (**C** and **D**) EFS and OS of the 23 patients with *DNMT3A*^mut^*/NPM1*^wild^. (**E** and **F**) EFS of the 28 patients with DNMT3A^mut^/NPM1^mut^.\
**Abbreviations:** EFS, event-free survival; HSCT, hematopoietic stem cell transplantation; OS, overall survival.](cmar-10-2489Fig3){#f3-cmar-10-2489}

![Influences of *FLT3-ITD/TKD* to the cohort.\
**Notes:** (**A** and **B**) EFS and OS of *DNMT3A*^mut^*/FLT3*^wild^*/NPM1*^wild^ vs *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^mut^ vs *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^wild^; *P*1 for comparison between *DNMT3A*^mut^*/FLT3*^wild^*/NPM1*^wild^ and *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^mut^; *P*2 for comparison between *DNMT3A*^mut^*/FLT3*^wild^*/NPM1*^wild^ vs *DNMT3A*^mut^*/FLT3*^mut^*/NPM1*^wild^.\
**Abbreviations:** EFS, event-free survival; OS, overall survival.](cmar-10-2489Fig4){#f4-cmar-10-2489}

###### 

Biological and clinical characteristics

  Characteristic            *DNMT3A*^mut^*/NPM1*^wild^, median (range) or n/%   *DNMT3A*^mut^*/NPM1*^mut^, median (range) or n/%   *t*/χ^2^                                             *P*
  ------------------------- --------------------------------------------------- -------------------------------------------------- ---------------------------------------------------- -------
  Age (years)               63 (42--81)                                         57 (21--81)                                        1.700[\*](#tfn1-cmar-10-2489){ref-type="table-fn"}   0.095
   \<60                     10/43.5                                             17/60.7                                                                                                 
   ≥60                      13/56.5                                             11/39.3                                                                                                 
  Gender                                                                                                                           0.440[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.580
   Male                     12/52.2                                             12/42.9                                                                                                 
   Female                   11/47.8                                             16/57.1                                                                                                 
  AML FAB subtypes                                                                                                                                                                      
   M0                       3/13.0                                              0                                                  3.880[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.085
   M1                       7/30.4                                              6/21.4                                             0.539[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.529
   M2                       5/21.7                                              6/21.4                                             0.001[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   M4                       5/21.7                                              7/25.0                                             0.075[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   M5                       2/8.7                                               9/32.1                                             4.104[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.084
   M7                       1/4.3                                               0                                                  1.242[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.451
  Karyotype                                                                                                                                                                             
   Normal                   10/43.5                                             23/85.2                                            9.628[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.003
   Complex                  3/13.0                                              1/3.7                                              1.472[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.322
   Trisomy 8                4/17.4                                              1/3.7                                              2.585[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.167
   −7/7q                    2/8.7                                               0                                                  2.446[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.207
   Others                   4/17.4                                              2/7.4                                              1.172[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.395
  Risk (cytogenetics)                                                                                                              3.224[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.121
   Good                     0                                                   0                                                                                                       
   Intermediate             17/73.9                                             25/92.6                                                                                                 
   Poor                     6/26.1                                              2/7.4                                                                                                   
  WBC count (×10^9^/L)      14.9 (1.2--202.7)                                   69.8 (2.6--298.4)                                  1.948[\*](#tfn1-cmar-10-2489){ref-type="table-fn"}   0.057
   \<50                     19/82.6                                             13/46.4                                                                                                 
   ≥50                      4/17.4                                              15/53.6                                                                                                 
  BM blasts                 62 (32--99)                                         81.5 (41--100)                                     2.531[\*](#tfn1-cmar-10-2489){ref-type="table-fn"}   0.015
   \<70                     14/60.9                                             7/25.0                                                                                                  
   ≥70                      9/39.1                                              21/75.0                                                                                                 
  PB blasts                 32 (0--97)                                          49 (0--91)                                         0.692[\*](#tfn1-cmar-10-2489){ref-type="table-fn"}   0.492
   \<70                     17/73.9                                             18/66.7                                                                                                 
   ≥70                      6/26.1                                              9/33.3                                                                                                  
  Relapse                   11/47.8                                             17/60.7                                            0.847[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.407
  Mutated recurrent genes   6 (2--10)                                           5 (2--11)                                          1.569[\*](#tfn1-cmar-10-2489){ref-type="table-fn"}   0.123
   \<5                      5/21.7                                              10/35.7                                                                                                 
   ≥5                       18/78.3                                             18/64.3                                                                                                 
  *FLT3*                                                                                                                           9.785[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.004
   *FLT3-ITD*               2/8.7                                               10/35.7                                                                                                 
   *FLT3-TKD*               2/8.7                                               7/25.0                                                                                                  
   Wild type                19/82.6                                             11/39.3                                                                                                 
  *IDH2*                                                                                                                           6.749[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.014
   Mutation                 5/21.7                                              0/0                                                                                                     
   Wild type                18/78.3                                             28/100                                                                                                  
  *IDH1*                                                                                                                           0.506[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.514
   Mutation                 6/26.1                                              5/17.9                                                                                                  
   Wild type                17/73.9                                             23/82.1                                                                                                 
  *TET2*                                                                                                                           4.015[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.079
   Mutation                 5/21.7                                              1/3.6                                                                                                   
   Wild type                18/78.3                                             27/96.4                                                                                                 
  *NRAS*                                                                                                                           0.058[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   Mutation                 2/8.7                                               3/10.7                                                                                                  
   Wild type                21/91.3                                             25/89.3                                                                                                 
  *CEBPA*                                                                                                                          0.599[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.583
   Single mutation          1/4.3                                               1/3.6                                                                                                   
   Double mutation          1/4.3                                               0/0                                                                                                     
   Wild type                21/91.3                                             27/96.4                                                                                                 
  *PTPN11*                                                                                                                         2.618[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.242
   Mutation                 0/0                                                 3/10.7                                                                                                  
   Wild type                23/100                                              25/89.3                                                                                                 
  *KRAS*                                                                                                                           0.042[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   Mutation                 2/8.7                                               2/7.1                                                                                                   
   Wild type                21/91.3                                             26/92.9                                                                                                 
  *U2AF1*                                                                                                                          0.599[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.583
   Mutation                 2/8.7                                               1/3.6                                                                                                   
   Wild type                21/91.3                                             27/96.4                                                                                                 
  *SMC1A*                                                                                                                          0.178[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   Mutation                 1/4.3                                               2/7.1                                                                                                   
   Wild type                22/95.7                                             26/92.9                                                                                                 
  *SMC3*                                                                                                                           0.066[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   Mutation                 3/13.0                                              3/10.7                                                                                                  
   Wild type                20/87.0                                             25/89.3                                                                                                 
  *RAD21*                                                                                                                          0.178[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    1.000
   Mutation                 1/4.3                                               2/7.1                                                                                                   
   Wild type                22/95.7                                             26/92.9                                                                                                 
  HSCT                                                                                                                             2.208[§](#tfn2-cmar-10-2489){ref-type="table-fn"}    0.166
   Yes                      13/56.5                                             10/35.7                                                                                                 
   Allo-HSCT                11/47.8                                             8/28.6                                                                                                  
   Auto-HSCT                2/8.7                                               2/7.1                                                                                                   
   No chemotherapy          10/43.5                                             18/64.3                                                                                                 

**Notes:**

Student's *t*-test.

Chi-square test.

**Abbreviations:** AML, acute myeloid leukemia; BM, bone marrow; FAB, French-American-British classification; HSCT, hematopoietic stem cell transplantation; PB, peripheral blood; WBC, white blood cell.

###### 

Kaplan--Meier analysis for EFS and OS between different biological and clinical character groups

  Characteristic            EFS (months)   OS (months)                                           
  ------------------------- -------------- ------------- ------- ------- ------- ------- ------- -------
  Age (years)                                                                                    
   \<60                     14.90          8.70          0.019   0.891   21.50   12.00   0.018   0.892
   ≥60                      17.20          2.50          1.863   0.172   8.40    6.30    2.319   0.128
  Risk (cytogenetics)                                                                            
   Intermediate             9.30           18.00         0.279   0.598   16.40   10.20   0.330   0.565
   Poor                     4.00           0.60          2.527   0.112   4.00    0.60    1.232   0.267
  WBC count (×10^9^/L)                                                                           
   \<50                     9.30           8.00          0.517   0.472   20.10   10.20   0.677   0.410
   ≥50                      4.00           7.50          1.632   0.201   6.60    7.90    0.739   0.390
  BM blasts (%)                                                                                  
   \<70                     9.60           7.80          1.153   0.283   20.20   10.20   1.188   0.276
   ≥70                      5.20           7.50          0.424   0.515   8.10    7.80    0.500   0.479
  PB blasts (%)                                                                                  
   \<70                     9.30           8.00          0.091   0.763   17.40   10.20   0.063   0.802
   ≥70                      4.00           5.70          0.072   0.789   6.60    7.50    0.020   0.888
  Mutated recurrent genes                                                                        
   \<5                      8.50           5.30          0.363   0.547   20.20   7.50    0.443   0.506
   ≥5                       8.60           8.20          0.059   0.807   15.80   10.20   0.055   0.815
  *FLT3-ITD/TKD*                                                                                 
   Present                  4.00           6.90          1.443   0.230   6.60    7.90    1.817   0.178
   Absent                   9.60           8.00          0.269   0.604   20.10   10.20   0.551   0.458
  *IDH1*                                                                                         
   Mutation                 4.90           13.80         1.134   0.287   5.20    24.80   1.781   0.182
   Wild type                9.30           6.90          1.620   0.203   16.40   7.50    1.910   0.167
  HSCT                                                                                           
   Yes                      14.90          10.20         0.006   0.938   21.50   16.30   0.005   0.942
   No                       5.90           5.30          0.006   0.940   7.70    6.30    0.071   0.790

**Abbreviations:** BM, bone marrow; EFS, event-free survival; HSCT, hematopoietic stem cell transplantation; OS, overall survival; PB, peripheral blood; WBC, white blood cell.
